Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication

What is this summary about? This is a summary of an article originally published in the European Respiratory Journal, which presented combined results from five retrospective real-world studies (i.e., studies looking at data collected during historical medical appointments) that each took place in a different country and which, together, formed the XALOC-1 study programme. XALOC-1 looked at how effective benralizumab injections were in real-world clinical practice at treating a type of asthma called ‘severe eosinophilic asthma’. What were the main results of the XALOC-1 study programme? Patients with severe eosinophilic asthma treated with benralizumab in the real world had a reduction in the number of asthma attacks, a reduction in their dose of steroid tablets (sometimes to zero), and improved lung function and asthma symptom control. This was true regardless of whether patients had or had not responded well to other biologic therapies before starting benralizumab. Patients who had nasal polyps or signs of allergy-related asthma also benefitted from treatment with benralizumab. What do the results of XALOC-1 mean? In real-world clinical practice (during medical appointments, rather than a specially designed clinical study), patients with severe eosinophilic asthma treated with benralizumab have reduced symptom severity and improved quality of life.

Authors

Institutions

Publication Details

Journal
Immunotherapy
Published
2025-01-22
DOI
https://doi.org/10.1080/1750743x.2025.2457931
Citations
1
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
1.16

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication

Douglas Arbetter, Vivian H. Shih, Benjamin Emmanuel, Trung N. Tran et al.
1 citations
Immunotherapy
Asthma and respiratory diseases
1.16
article

Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication

Douglas Arbetter, Vivian H. Shih, Benjamin Emmanuel, Trung N. Tran, Marisa Pardal, Alicia Padilla‐Galo, Adrian Rabe, Anat Shavit, Sheena Kayaniyil, Michael Watt, Silvia Boarino, David J. Jackson, Javier Nuevo, Rohit Katial, Cláudia Chaves Loureiro, David Cohen, Esther García Gil, Girolamo Pelaia
article en
1 citations

Abstract

What is this summary about? This is a summary of an article originally published in the European Respiratory Journal, which presented combined results from five retrospective real-world studies (i.e., studies looking at data collected during historical medical appointments) that each took place in a different country and which, together, formed the XALOC-1 study programme. XALOC-1 looked at how effective benralizumab injections were in real-world clinical practice at treating a type of asthma called ‘severe eosinophilic asthma’. What were the main results of the XALOC-1 study programme? Patients with severe eosinophilic asthma treated with benralizumab in the real world had a reduction in the number of asthma attacks, a reduction in their dose of steroid tablets (sometimes to zero), and improved lung function and asthma symptom control. This was true regardless of whether patients had or had not responded well to other biologic therapies before starting benralizumab. Patients who had nasal polyps or signs of allergy-related asthma also benefitted from treatment with benralizumab. What do the results of XALOC-1 mean? In real-world clinical practice (during medical appointments, rather than a specially designed clinical study), patients with severe eosinophilic asthma treated with benralizumab have reduced symptom severity and improved quality of life.

ImmunotherapyVol. 17(2)
AstraZeneca (United Kingdom) (GB), King's College London (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Hospitais da Universidade de Coimbra (PT), National Jewish Health (US), Magna Graecia University (IT), Insmed (United States) (US), Almirall (Spain) (ES), The London College (GB), AstraZeneca (Spain) (ES), AstraZeneca (Canada) (CA), AstraZeneca (United States) (US), Hospital Clínico Universitario Virgen de la Victoria (ES), AstraZeneca (Portugal) (PT), Imperial College London (GB), University of Colorado Denver (US)
AstraZeneca, McGill University, McMaster University
Zero hunger
Openalex Percentile: Top 26%
Asthma and respiratory diseases
1.16
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.